Predicting hepatorenal syndrome in cirrhotic patients using biomarkers
Official title: Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Run by The University of Hong Kong · NCT02434445 · Data updated 2026-11-12
This study is trying to see if new blood and urine tests can help predict if patients with advanced liver disease will develop kidney problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | June 1, 2012 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | December 16, 2024 |
| Trial ID | NCT02434445 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with advanced cirrhosis (Child's B or C) who are referred for liver transplantation.
✕Probably not a fit
Patients with co-existing renal diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of novel plasma and urinary biomarkers to predict the development of hepatorenal syndrome in patients with advanced cirrhosis. It focuses on biomarkers such as plasma cystatin C, plasma NGAL, and urinary KIM-1, among others. The study compares biomarker levels in advanced cirrhotic patients who have developed hepatorenal syndrome with those who have not. The goal is to correlate these biomarkers with the occurrence of hepatorenal syndrome to improve predictive capabilities.
Why it matters
Potential benefit: If successful, this study could lead to earlier identification and management of hepatorenal syndrome in cirrhotic patients, potentially improving patient outcomes.
How similar studies have gone: Other studies have explored biomarkers in similar contexts, but the specific combination and predictive capability of these biomarkers in this population is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation * Willing to give informed consent Exclusion Criteria: * Patients with co-existing renal diseases
Where it's running
-
Queen Mary Hospital, Hong Kong
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: Desmond Yap, MD — The University of Hong Kong
- Study coordinator: Desmond Yap, MD
- Email: desmondy@hku.hk
- Phone: 85222553879
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating fluid treatment strategies for kidney injury in cirrhosis patients
This study is testing two different ways to give IV fluids to people with kidney injury and cirrhosis to see which method helps them feel better and survive longer.
-
Analysis of outcomes in patients with Hepatorenal Syndrome
This study looks at how patients with Hepatorenal Syndrome are doing over four years to see how different treatments affect their health.
-
TIPS treatment for patients with cirrhosis and acute kidney injury
This study is testing if a procedure called TIPS can help people with liver cirrhosis and kidney problems feel better compared to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.